A Phase 4 interventional study of Levetiracetam and Topiramate in Epilepsy, sponsored by UCB Korea Co., Ltd.. Completed at 24 sites in Korea, Republic of. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-15.
Sponsored by UCB Korea Co., Ltd. (part of UCB S.A.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.
Among the 60 studies testing levetiracetam in Epilepsy, this one is the 10th largest by enrollment, is one of 4 that started in 2010, is one of 13 in phase 4, and was the 37th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Waad Alkathiri · Sites in Saudi Arabia
Ages 18+
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
National Taiwan University Hospital
Ages 20+
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 16 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 28 · Phase 4 13
First in 1998; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 343 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 94 across the 60 interventional studies. Of the 55 that completed or were terminated, 31 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Korea Co., Ltd., one of the names counted as UCB S.A.. Under that name alone:
UCB Korea Co., Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.
128 studies in Epilepsy by UCB S.A.: 2 open now, 2 under way, 2 of them phase 3. Of 121 finished, 90 (74%) have results posted.
Among the 128 studies in Epilepsy by UCB S.A., this one is the 28th largest by enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2010, is one of 7 in phase 4, and was the 68th registered.
UCB S.A.’s Epilepsy studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing levetiracetam in Epilepsy, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 128 in Epilepsy:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the long-term effects of levetiracetam on retention rate in subjects with refractory partial onset seizure that are not fully controlled with 1 to 3 concomitant antiepileptic drugs, compared to topiramate as add-on therapy during 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
250 mg and 500 mg levetiracetam tablet; titration from 1000 mg/day (500 mg bid) to 3000 mg/day (1500 mg bid) levetiracetam with treatment duration up to 52 weeks
Drug: Levetiracetam
25 mg and 100 mg topiramate tablet; titration from 100 mg/day (50 mg bid) to 400 mg/day (200 mg bid) topiramate with treatment duration up to 52 weeks
Drug: Topiramate
250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
Also known as: Keppra
25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
Percentage of Subjects Continuing the Allocated Investigational Treatment From the First Study Treatment Intake to Week 52, After the Beginning of Investigational Treatment With Levetiracetam Compared to Topiramate
Time frame: From Baseline to Week 52
Number of Subjects With at Least One Adverse Event Reported During the Trial Period From Baseline to Week 52
Time frame: From Baseline to Week 52
Time From the First Study Treatment Intake to Drug Discontinuation Due to Adverse Event (AE)
Time frame: From Baseline to Week 52
Median Percent Reduction in the Weekly Partial Onset Seizure (POS) Frequency From Baseline During the Total Treatment Period From Baseline to Week 52
Reduction from baseline was defined as baseline value minus post-baseline value and therefore is the negative of the change from baseline value.
Time frame: From Baseline to Week 52
Responders Defined as Number of Subjects With at Least 50 % Reduction in the Weekly POS Frequency From Baseline During the Total Treatment Period From Baseline to Week 52
Time frame: From Baseline to Week 52
447 subjects were screened, 343 subjects were randomized.
| Milestone | Levetiracetam | Topiramate |
|---|---|---|
| Started | 177 | 166 |
| Completed | 111 | 100 |
| Not completed | 66 | 66 |
| Withdrew: Lack of efficacy | 8 | 8 |
| Withdrew: Protocol violation | 13 | 8 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Withdrawal by subject | 18 | 17 |
| Withdrew: Other reason | 13 | 10 |
| Withdrew: Sae, non-fatal | 0 | 4 |
| Withdrew: Ae, non-serious non-fatal | 13 | 17 |
| Withdrew: Sae, non-fatal+ae, non-serious non-fatal | 1 | 0 |
| percentage of subjects | Levetiracetam (Full Analysis Set) | Topiramate (Full Analysis Set) |
|---|---|---|
| Percentage of Subjects Continuing the Allocated Investigational Treatment From the First Study Treatment Intake to Week 52, After the Beginning of Investigational Treatment With Levetiracetam Compared to Topiramate | 59.1 | 56.6 |
| Participants | Levetiracetam | Topiramate |
|---|---|---|
| Number of Subjects With at Least One Adverse Event Reported During the Trial Period From Baseline to Week 52 | 125 | 128 |
| month | Levetiracetam | Topiramate |
|---|---|---|
| Time From the First Study Treatment Intake to Drug Discontinuation Due to Adverse Event (AE) | NA (NA to NA) | NA (NA to NA) |
Reduction from baseline was defined as baseline value minus post-baseline value and therefore is the negative of the change from baseline value.
| percent reduction | Levetiracetam (Full Analysis Set) | Topiramate (Full Analysis Set) |
|---|---|---|
| Median Percent Reduction in the Weekly Partial Onset Seizure (POS) Frequency From Baseline During the Total Treatment Period From Baseline to Week 52 | 74.47 (38.00 to 96.28) | 67.86 (29.21 to 87.24) |
| responders | Levetiracetam (Full Analysis Set) | Topiramate (Full Analysis Set) |
|---|---|---|
| Responders Defined as Number of Subjects With at Least 50 % Reduction in the Weekly POS Frequency From Baseline During the Total Treatment Period From Baseline to Week 52 | 120 | 107 |
Collected over Adverse Events (AEs) were collected from Visit 1 (Week -4) until final Visit 12 (Week 53).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levetiracetam | — | 10/177 (5.6%) | 86/177 (48.6%) |
| Topiramate | — | 15/166 (9%) | 91/166 (54.8%) |
| Event | Levetiracetam | Topiramate |
|---|---|---|
| SeizureNervous system disorders | 1/177 | 5/166 |
| DizzinessNervous system disorders | 2/177 | 0/166 |
| Duodenal ulcerGastrointestinal disorders | 0/177 | 1/166 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/177 | 1/166 |
| Pancreatitis acuteGastrointestinal disorders | 0/177 | 1/166 |
| PneumoniaInfections and infestations | 0/177 | 1/166 |
| Joint dislocationInjury, poisoning and procedural complications | 0/177 | 1/166 |
| Radius fractureInjury, poisoning and procedural complications | 0/177 | 1/166 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/177 | 1/166 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/177 | 1/166 |
| Event | Levetiracetam | Topiramate |
|---|---|---|
| SomnolenceNervous system disorders | 36/177 | 20/166 |
| DizzinessNervous system disorders | 30/177 | 24/166 |
| Decreased appetiteMetabolism and nutrition disorders | 3/177 | 26/166 |
| HeadacheNervous system disorders | 17/177 | 24/166 |
| NasopharyngitisInfections and infestations | 24/177 | 16/166 |
| Weight decreasedInvestigations | 3/177 | 17/166 |
| ParaesthesiaNervous system disorders | 2/177 | 16/166 |
| NauseaGastrointestinal disorders | 9/177 | 10/166 |
| Memory impairmentNervous system disorders | 1/177 | 9/166 |
| DyspepsiaGastrointestinal disorders | 9/177 | 7/166 |
The Baseline Characteristics refers to the Safety Set which consists of all subjects who were randomized and received at least 1 dose of trial medication.
| Age, Categorical(Participants) | Levetiracetam | Topiramate | Total Title |
|---|---|---|---|
| <=18 years | 4 | 0 | 4 |
| Between 18 and 65 years | 165 | 162 | 327 |
| >=65 years | 8 | 4 | 12 |
| Age, Continuous(years) | Levetiracetam | Topiramate | Total Title |
|---|---|---|---|
| Mean | 40.9 ± 13.6 | 39.7 ± 11.8 | 40.3 ± 12.8 |
| Sex: Female, Male(Participants) | Levetiracetam | Topiramate | Total Title |
|---|---|---|---|
| Female | 71 | 64 | 135 |
| Male | 106 | 102 | 208 |
The record gives a start of Nov 2010, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam